A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft ModelsXiaomei Zhang, Michael T. Lewis, Sofie Claerhout et al.|Cancer Research|2013Cited by 485
Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 TherapyMario Giuliano, Rachel Schiff, Huizhong Hu et al.|Clinical Cancer Research|2015Cited by 119
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancerMothaffar F. Rimawi, Rachel Schiff, Carmine De Angelis et al.|Breast Cancer Research and Treatment|2017Cited by 95
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinaseXiaoyong Fu, Rachel Schiff, Chad J. Creighton et al.|Breast Cancer Research|2014Cited by 70
Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasisMario Giuliano, Meghana V. Trivedi, Sabrina Herrera et al.|Breast Cancer Research|2015Cited by 57